Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Arthritis, Rheumatoid
Interventions: FKB327, Humira®; Drug
Lead sponsor: Fujifilm Kyowa Kirin Biologics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Peoria, Arizona • Palm Desert, California • Boca Raton, Florida + 13 more

Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Interventions: NS-018, Best Available Therapy; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Worcester, Massachusetts • Houston, Texas

Conditions: Migraine, Headache
Interventions: Magnesium Sulfate, Metoclopramide 10mg, Prochlorperazine (Compazine) Injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Aphasia, Acquired
Interventions: Conversation Treatment for Aphasia; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 85 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • Maywood, New Jersey • Philadelphia, Pennsylvania

Conditions: Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions: Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results; Other
Lead sponsor: Proove Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 31
States / cities: Beverly Hills, California • Fresno, California • La Jolla, California + 23 more

Conditions: Nicotine Dependence, Cigarettes
Interventions: AI-enhanced smartphone app, AI-enhanced smartphone app, but with delayed access; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 14 Years to 20 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Major Depressive Disorder
Interventions: AXS-05, Bupropion; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 40
States / cities: Bellflower, California • Lafayette, California • Oceanside, California + 34 more

Conditions: Essential Thrombocythemia
Interventions: Ropeginterferon alfa-2b, Anagrelide; Biological · Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Aggression, Self-injurious Behavior
Interventions: Trad FCT, Mult FCT, Mult FCT + Stimulus Fading; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Allergic Conjunctivitis
Interventions: Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 6
States / cities: Phoenix, Arizona • Torrance, California • Andover, Massachusetts + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®); Drug
Lead sponsor: Lupin, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more

Conditions: Hypoparathyroidism
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Incontinence, Urge, Urinary Incontinence in Old Age
Interventions: Mindfulness-Based Stress Reduction, Health Enhancement Program; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 55 Years to 105 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Coronary Syndrome (ACS)
Interventions: REG1, Heparin; Drug
Lead sponsor: Regado Biosciences, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 26
States / cities: Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more

Conditions: Dental Plaque
Interventions: Fluoride, Triclosan, fluoride, Metal salt; Drug · Other
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Cedar Knolls, New Jersey

Conditions: Menorrhagia
Interventions: Naproxen, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Insomnia, Health Adult Subjects, Insomnia Disorder, Heart Health Markers
Interventions: Vinyasa yoga, Gentle yoga, Non-active control; Behavioral · Other
Lead sponsor: Caitlin Cheruka; Other
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Diabetes
Interventions: Large Envelope, Priority Mail, Amazon; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sepsis, Severe Sepsis, Septic Shock
Interventions: HindSight, InSight; Other
Lead sponsor: Dascena; Industry
Eligibility: 18 Years and older
Enrollment: 37,986 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Springfield, Massachusetts • Camden, New Jersey • Cape May, New Jersey

Conditions: Overweight, Obesity
Interventions: Disseminating Effective Habits for Long-term Weight Loss, Achieve Together website; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Post-menopause
Interventions: Study Procedures; Other
Lead sponsor: Emory University; Other
Eligibility: 45 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Smoking
Interventions: mTHS 2.2, mCC, NNS; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm, Mast Cell Leukemia
Interventions: Not listed
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Palo Alto, California • Boston, Massachusetts

Search by objective public record fields.

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

Conversation Group Treatment for Aphasia: Does it Work?

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

AI-Enhanced App-based Intervention for Adolescent E-cigarette Cessation

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Refinements of Functional Communication Training

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Hypoparathyroidism Natural History Study

Comparing Approaches to Treat Older Adult Women's Urge Incontinence: Pilot Feasibility and Randomized Controlled Trial

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

Compare the Clinical Efficacy of Prototype Toothpastes

Copper IUD Treatment Observation Study

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Does Style Matter: Comparison of Moderate- to Low-intensity Styles of Yoga

Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study

Machine Learning Sepsis Alert Notification Using Clinical Data

Disseminating Effective Habits for Long-Term Weight Loss

Mental Stress Reactivity in Women With CMD

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM